Stockreport

BRIEF-AGTC Doses First Patient In Phase 1/2 Clinical Study Of Gene Therapy For Treatment Of X-Linked Retinitis Pigmentosa [Reuters]

Applied Genetic Technologies Corporation  (AGTC) 
Last applied genetic technologies corporation earnings: 2/5 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.agtc.com/investor-relations
PDF BRIEF-AGTC Doses First Patient In Phase 1/2 Clinical Study Of Gene Therapy For Treatment Of X-Linked Retinitis Pigmentosa | Reuters Reuters Staff 1 Min Read April 18 (Re [Read more]